Reimagining Manufacturing for Pandemic Preparedness: Non-Paper on Public Private Partnerships for the High-Level Independent Panel on Financing the Global Commons for Pandemic Preparedness and Response   [open pdf - 0B]

From the Summary: "The COVID-19 [coronavirus disease 2019] pandemic illuminated longstanding challenges in our global ability to respond to pandemic threats, including a global biopharmaceutical manufacturing ecosystem unprepared for crisis response. The lack of manufacturing capacity for vaccines and therapeutics poses a public health risk to the world and prevents new medicines from reaching patients as fast as possible. As the global community looks to prevent, prepare for, and respond to future pandemics, it must commit to a new future for biopharmaceutical manufacturing that reimagines how medicines are made. A sustainable ecosystem for biopharmaceutical manufacturing requires new manufacturing technologies and flexible, distributed production systems that can respond to diverse disease threats at speed and at scale. Public-private partnerships play a vital role in bringing together the innovation, infrastructure, and human capital that make this new ecosystem possible. This non-paper outlines how biopharmaceutical manufacturing must be enhanced and ways the public and private sector can partner to build flexible, multi-modality manufacturing capacity, invest in novel technologies, and advance manufacturing science."

National Resilience, Inc.; G20 HLIP
Retrieved From:
Financing the Global Commons for Pandemic Preparedness and Response: https://pandemic-financing.org/
Media Type:
Help with citations